The cardiovascular nutrapharmacology of resveratrol: Pharmacokinetics, molecular mechanisms and therapeutic potential

Current Medicinal Chemistry

Volumn 17, Issue 23, 2010, Pages 2442-2455

  Kroon, Paul A ^a   Iyer, Abishek ^b   Chunduri, Prasad ^b,d   Chan, Vincent ^c   Brown, Lindsay ^b,c  

^a NORWICH RESEARCH PARK   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^d TAYLOR S UNIVERSITY   (Malaysia)

Author keywords

cardiovascular remodelling; preconditioning; Resveratrol; sirtuins

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; NITRIC OXIDE; POLYPHENOL; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN; THIOREDOXIN;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BILE FLOW; CARDIOMYOPATHY; CARDIOVASCULAR RESPONSE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TRANSPORT; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTESTINE ABSORPTION; NONHUMAN; PROTEIN TARGETING; RED WINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TISSUE DISTRIBUTION; URINARY EXCRETION; VASODILATATION;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; STILBENES;

EID: 77954363244     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791556032     Document Type: Article

References (127)

1. Van Horn, L.; McCoin, M.; Kris-Etherton, P.M.; Burke, F.; Carson, J.S.; Champagne, C.M.; Karmally, W.; Sikand, G. The evidence for dietary prevention and treatment of cardiovascular disease. J. Am. Diet. Assoc., 2008, 108, 287-331.
2. Getz, G.S.; Reardon, C.A. Nutrition and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2499-2506.
3. Zarraga, I.G.E.; Schwarz, E.R. Impact of dietary patterns and interventions on cardiovascular health. Circulation, 2006, 114, 961-973.
4. Keys, A. Coronary heart disease in seven countries. Circulation, 1970, 44 (Supp 1), 1-211.
5. German, J.B.; Walzem, R.L. The health benefits of wine. Annu. Rev. Nutr. 2000, 20, 561-593.
6. De Lorgeril, M.; Salen, P.; Martin, J-L.; Monjaud, I.; Delaye, J.; Mamelle, N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation, 1999, 99, 779-785.
7. De Lorgeril, M.; Salen, P. The Mediterranean diet in secondary prevention of coronary heart disease. Clin. Invest. Med., 2006, 29, 154-158.
8. Bertelli, A.A.; Das, D.K. Grapes, wines, resveratrol, and heart health. J. Cardiovasc. Pharmacol., 2009, 54, 468-476.
9. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet, 1992, 339, 1523-1526.
10. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov., 2006, 5, 493-506.
11. Das, D.K.; Maulik, N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., 2006, 6, 36-47.
12. Das, S.; Das, D.K. Resveratrol: a therapeutic promise for cardiovascular disease. Recent Pat. Cardiovasc. Drug. Discov., 2007, 2, 133-138.
13. Opie, L.H.; Lecour, S. The red wine hypothesis: from concepts to protective signalling molecules. Eur. Heart J., 2007, 28, 1683-1693.
14. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24, 493-506.
15. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T. Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res., 2008, 658, 68-94.
16. Raval, A.P.; Lin, H.W.; Dave, K.R.; DeFazio, R.A.; Della Morte, D.; Kim, E.J.; Perez-Pinzon, M.A. Resveratrol and ischemic preconditioning in the brain. Curr. Med. Chem., 2008, 15, 1545-1551.
17. Harikumar, K.B.; Aggarwal, B.B. Resveratrol. A multitargeted agent for age-associated chronic diseases. Cell Cycle, 2008, 7, 1020-1035.
18. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-342.
19. Alcain, F.J.; Villalba, J.M. Sirtuin activators. Expert. Opin. Ther. Pat., 2009, 19, 403-414.
20. Pearson, K.J.; Baur, J.A.; Lewis, K.N.; Peshkin, L.; Price, N.L.; Labinskyy, N.; Swindell, W.R.; Kamara, D.; Minor, R.K.; Perez, E.; Jamieson, H.A.; Zhang, Y.; Dunn, S.R.; Sharma, K.; Pleshko, N.; Woollett, L.A.; Csiszar, A.; Ikeno, Y.; Le Couteur, D.; Elliott, P.J.; Becker, K.G.; Navas, P.; Ingram, D.K.; Wolf, N.S.; Ungvari, Z.; Sinclair, D.A.; de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metabol., 2008, 8, 157-168.
21. de la Lastra, C.A.; Villegas, I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res., 2005, 49, 405-430.
22. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.F.; Nunes, T.; Wright, L.; Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res., 2009, 53, S7-15.
23. Blardi, P.; De Lalla, A.; Volpi, L.; Di Perri, T. Stimulation of endogenous adenosine release by oral administration of quercetin and resveratrol in man. Drugs. Exp. Clin. Res., 1999, 25, 105-110.
24. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P.; Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer. Epidemiol. Biomarkers Prev., 2007, 16, 1246-1252.
25. Burkon, A.; Somoza, V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol- C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol. Nutr. Food. Res., 2008, 52, 549-557.
26. Soleas, G.J.; Yan, J.; Goldberg, D.M. Measurement of transresveratrol, (+)-catechin, and quercetin in rat and human blood and urine by gas chromatography with mass selective detection. Methods Enzymol., 2001, 335, 130-145.
27. Halls, C.; Yu, O. Potential for metabolic engineering of resveratrol biosynthesis. Trends. Biotechnol., 2008, 26, 77-81.
28. Giovinazzo, G.; D'Amico, L.; Paradiso, A.; Bollini, R.; Sparvoli, F.; DeGara, L. Antioxidant metabolite profiles in tomato fruit constitutively expressing the grapevine stilbene synthase gene. Plant Biotech. J., 2005, 3, 57-69.
29. Ferré-Filmon, K.; Delaude, L.; Demonceau, A.; Noels, A.F. Stereoselective Synthesis of (E)-hydroxystilbenoids by rutheniumcatalyzed cross-metathesis. Eur. J. Org. Chem., 2005, 15, 3319-3325.
30. Lappano, R.; Rosano, C.; Madeo, A.; Albanito, L.; Plastina, P.; Gabriele, B.; Forti, L.; Stivala, L.A.; Iacopetta, D.; Dolce, V.; Ando, S.; Pezzi, V.; Maggiolini, M. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food. Res., 2009, 53, 845-858.
31. Kroon, P.A.; Clifford, M.N.; Crozier, A.; Day, A.J.; Donovan, J.L.; Manach, C.; Williamson, G. How should we assess the effects of exposure to dietary polyphenols in vitro? Am. J. Clin. Nutr., 2004, 80, 15-21.
32. Manach, C.; Scalbert, A.; Morand, C.; Rémésy, C.; Jiménez, L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr., 2004, 79, 727-747.
33. Goldberg, D.M.; Yan, J.; Soleas, G.J. Absorption of three winerelated polyphenols in three different matrices by healthy subjects. Clin. Biochem., 2003, 36, 79-87.
34. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E. Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32, 1377-1382.
35. Walle, T.; Walle, U.K.; Halushka, P.V. Carbon dioxide is the major metabolite of quercetin in humans. J. Nutr., 2001, 131, 264826-264852.
36. Janisch, K.M.; Williamson, G.; Needs, P.; Plumb, G.W. Properties of quercetin conjugates: modulation of LDL oxidation and binding to human serum albumin. Free Radic. Res., 2004, 38, 877-884.
37. Jannin, B.; Menzel, M.; Berlot, J.P.; Delmas, D.; Lançon, A.; Latruffe, N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem. Pharmacol., 2004, 68, 1113-1118.
38. Urpí-Sardà, M.; Jáuregui, O.; Lamuela-Raventós, R.M.; Jaeger, W.; Miksits, M.; Covas, M.I.; Andres-Lacueva, C. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem., 2005, 77, 3149-3155.
39. Vitrac, X.; Desmoulière, A.; Brouillaud, B.; Krisa, S.; Deffieux, G.; Barthe, N.; Rosenbaum, J.; Mérillon, J.M. Distribution of [14C]- trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci., 2003, 72, 2219-2233.
40. El-Mohsen, A.M.; Bayele, H.; Kuhnle, G.; Gibson, G.; Debnam, E.; Kaila Srai, S.; Rice-Evans, C.; Spencer, J.P. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr., 2006, 96, 62-70.
41. Nemeth, K.; Plumb, G.W.; Berrin, J.G.; Juge, N.; Jacob, R.; Naim, H.Y.; Williamson, G.; Swallow, D.M.; Kroon, P.A. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr., 2003, 42, 29-42.
42. Marier, J.F.; Vachon, P.; Gritsas, A.; Zhang, J.; Moreau, J.P.; Ducharme, M.P. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther., 2002, 302, 369-373.
43. Kaldas, M.I.; Walle, U.K.; Walle, T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol., 2003, 55, 307-312.
44. Maier-Salamon, A.; Hagenauer, B.; Wirth, M.; Gabor, F.; Szekeres, T.; Jager, W. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res., 2006, 23, 2107-2115.
45. De Santi, C.; Pietrabissa, A.; Spisni, R.; Mosca, F.; Pacifici, G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica, 2000, 30, 857-866.
46. De Santi, C.; Pietrabissa, A.; Mosca, F.; Pacifici, GM. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica, 2000, 30, 1047-1054.
47. Yu, C.; Shin, Y.G.; Chow, A.; Li, Y.; Kosmeder, J.W.; Lee, Y.S.; Hirschelman, W.H.; Pezzuto, J.M.; Mehta, R.G.; van Breemen, R.B. Human, rat, and mouse metabolism of resveratrol. Pharm. Res., 2002, 19, 1907-1914.
48. Lançon, A.; Hanet, N.; Jannin, B.; Delmas, D.; Heydel, J.M.; Lizard, G.; Chagnon, M.C.; Artur, Y.; Latruffe, N. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos., 2007, 35, 699-703.
49. Murias, M.; Miksits, M.; Aust, S.; Spatzenegger, M.; Thalhammer, T.; Szekeres, T.; Jaeger, W. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett., 2008, 26, 172-182.
50. Potter, G.A.; Patterson, L.H.; Wanogho, E.; Perry, P.J.; Butler, P.C.; Ijaz, T.; Ruparelia, K.C.; Lamb, J.H.; Farmer, P.B.; Stanley, L.A.; Burke, M.D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer, 2002, 86, 774-778.
51. Piver, B.; Fer, M.; Vitrac, X.; Merillon, J.M.; Dreano, Y.; Berthou, F.; Lucas, D. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem. Pharmacol., 2004, 68, 773-782.
52. Ciolino, H.P.; Daschner, P.J.; Yeh, G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res.,1998, 58, 5707-5712.
53. Yueh, M.F.; Kawahara, M.; Raucy, J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol. In Vitro., 2005, 19, 275-287.
54. Vidavalur, R.; Otani, H.; Singal, P.K.; Maulik, N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp. Clin. Cardiol., 2006, 11, 217-225.
55. Pervaiz, S.; Holme, A.L.; Aggarwal, B.B.; Anekonda, T.S.; Baur, J.A.; Gojkovic-Bukarica, L.; Ragione, F.D.; Kim, A.L.; Pirola, L.; Saiko, P. Resveratrol: its biologic targets and functional activity. Antioxid. Redox. Signal., 2009, 11, 2851-2897.
56. Das, S.; Khan, N.; Mukherjee, S.; Bagchi, D.; Gurusamy, N.; Swartz, H.; Das, D.K. Redox regulation of resveratrol-mediated switching of death signal into survival signal. Free Radic. Biol. Med., 2008, 44, 82-90.
57. Dudley, J.; Das, S.; Mukherjee, S.; Das, D.K. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J. Nutr. Biochem., 2009, 20, 443-452.
58. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M.L.; Rehman, M.; Walther, T.C.; Olsen, J.V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 2009, 325, 834-840.
59. Finkel, T.; Deng, C.X.; Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature, 2009, 460, 587-591.
60. Brunet, A.; Sweeney, L.B.; Sturgill, J.F.; Chua, K.F.; Greer, P.L.; Lin, Y.; Tran, H.; Ross, S.E.; Mostoslavsky, R.; Cohen, H.Y.; Hu, L.S.; Cheng, H.L.; Jedrychowski, M.P.; Gygi, S.P.; Sinclair, D.A.; Alt, F.W.; Greenberg, M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 2004, 303, 2011-2015.
61. Hsu, C.P.; Odewale, I.; Alcendor, R.R.; Sadoshima, J. Sirt1 protects the heart from aging and stress. Biol. Chem., 2008, 389, 221-231.
62. Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S.F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 2007, 100, 1512-1521.
63. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J.; Westphal, C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450, 712-716.
64. Milne, J.C.; Denu, J.M. The sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol., 2008, 12, 11-17.
65. Knutson, M.D.; Leeuwenburgh, C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr. Rev., 2008, 66, 591-596.
66. Baur, J.A. Biochemical effects of SIRT1 activators. Biochim. Biophys. Acta, 2009, doi:10.1016/j.bbapap.2009.10.025.
67. Jiang, W-J. Sirtuins: Novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun., 2008, 373, 341-344.
68. Feige, J.N.; Lagouge, M.; Canto, C.; Strehle, A.; Houten, S.M.; Milne, J.C.; Lambert, P.D.; Mataki, C.; Elliott, P.J.; Auwerx, J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metabolism, 2008, 8, 347-358.
69. Smith, J.J.; Kenney, R.D.; Gagne, D.J.; Frushour, B.P.; Ladd, W.; Galonek, H.L.; Israelian, K.; Song, J.; Razvadauskaite, G.; Lynch, A.V.; Carney, D.P.; Johnson, R.J.; Lavu, S.; Iffland, A.; Elliott, P.J.; Lambert, P.D.; Elliston, K.O.; Jirousek, M.R.; Milne, J.C.; Boss, O. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol., 2009, 3, 31.
70. Jia, Z.; Zhu, H.; Misra, B.R.; Mahaney, J.E.; Li, Y.; Misra, H.P. EPR studies on the superoxide-scavenging capacity of the nutraceutical resveratrol. Mol. Cell Biochem., 2008, 313, 187-194.
71. Das, S.; Alagappan, V.K.T.; Dagchi, D.; Sharma, H.S.; Maulik, N.; Das, D.K. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption. A potential mechanism for resveratrol preconditioning of the heart. Vasc. Pharmacol., 2005, 42, 281-289.
72. Gresele, P.; Pignatelli, P.; Guglielmini, G.; Carnevale, R.; Mezzasoma, A.M.; Ghiselli, A.; Momi, S.; Violi, F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J. Nutr., 2008, 138, 1602-1608.
73. Brito, P.M.; Mariano, A.; Almeida, L.M.; Dinis, T.C. Resveratrol affords protection against peroxynitrite-mediated endothelial cell death: A role for intracellular glutathione. Chem. Biol. Interact., 2006, 164, 157-166.
74. Cao, Z.; Li, Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol., 2004, 489, 39-48.
75. Orallo, F.; Alvarez, E.; Camina, M.; Leiro, J.M.; Gomez, E.; Fernandez, P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol. Pharmacol., 2002, 61, 294-302.
76. Maulik, N.; Das, D.K. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim. Biophys. Acta., 2008, 1780, 1368-1382.
77. Das, S.; Khan, N.; Mukherjee, S.; Bagchi, D.; Gurusamy, N.; Swartz, H.; Das, D.K. Redox regulation of resveratrol-mediated switching of death signal into survival signal. Free Radic. Biol. Med., 2008, 44, 82-90.
78. Bolli, R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H19-27.
79. Das, S.; Tosaki, A.; Bagchi, D.; Maulik, N.; Das, D.K. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J. Pharmacol. Exp. Ther., 2006, 317, 980-988.
80. Raval, A.P.; Dave, K.R.; Pérez-Pinzón, M.A. Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab., 2006, 26, 1141-1147.
81. Das, S.; Cordis, G.A.; Maulik, N.; Das, D.K. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H328-335.
82. Das, S.; Tosaki, A.; Bagchi, D.; Maulik, N.; Das, D.K. Resveratrolmediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J. Pharmacol. Exp. Ther., 2005, 314, 762-769.
83. Das, S.; Fraga, C.G.; Das, D.K. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFβB. Free Radic. Res., 2006, 40, 1066-1075.
84. Thirunavukkarasu, M.; Penumathsa, S.V.; Koneru, S.; Juhasz, B.; Zhan, L.; Otani, H.; Bagchi, D.; Das, D.K.; Maulik, N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free. Radic. Biol. Med., 2007, 43, 720-729.
85. Penumathsa, S.V.; Thirunavukkarasu, M.; Zhan, L.; Maulik, G.; Menon, V.P.; Bagchi, D.; Maulik, N. Resveratrol enhances GLUT- 4 translocation to the caveolar lipid raft fractions through AMPK/AKT/eNOS signaling pathway in diabetic myocardium. J. Cell Mol. Med., 2008, 12, 2350-2361.
86. Miatello, R.; Vázquez, M.; Renna, N.; Cruzado, M.; Ponce Zumino, A.; Risler, N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens., 2005, 18, 864-870.
87. Lekli, I.; Szabo, G.; Juhasz, B.; Das, S.; Das, M.; Varga, E.; Szendrei, L.; Gesztelyi, R.; Varadi, J.; Bak, I.; Das, D.K.; Tosaki, A. Protective mechanisms of resveratrol against ischemiareperfusion- induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, H859-H866.
88. Chan, A.Y.; Dolinsky, V.W.; Soltys, C.L.; Viollet, B.; Baksh, S.; Light, P.E.; Dyck, J.R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem., 2008, 283, 24194-24201.
89. El-Mowafy, A.M.; Alkhalaf, M.; El-Kashef, H.A. Resveratrol reverses hydrogen peroxide-induced proliferative effects in human coronary smooth muscle cells: a novel signalling mechanism. Arch. Med. Res., 2008, 39, 155-161.
90. Mizutani, K.; Ikeda, K.; Yamori, Y. Resveratrol inhibits AGEsinduced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem. Biophys. Res. Commun., 2000, 274, 61-67.
91. Juric, D.; Wojciechowski, P.; Das, D.K.; Netticandan, T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am. J. Physiol. Heart. Circ. Physiol., 2007, 292, H2138-H2143.
92. Burstein, B.; Maguy, A.; Clement, R.; Gosselin, H.; Poulin, F.; Ethier, N.; Tardif, J.C.; Hebert, T.E.; Calderone, A.; Nattel, S. Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J. Pharmacol. Exp. Ther., 2007, 323, 916-923.
93. Olson, E.R;. Naugle, J.E.; Zhang, X.; Bomser, J.A.; Meszaros, J.G. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am. J. Physiol., 2005, 288, H1131-H1138.
94. Wang, S.J.; Wang, X.X.; Yan, J.; Xie, X.D.; Fan, F.H.; Zhou, X.; Han, L.; Chen, J.Z. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts: correlated with NO-cGMP signaling pathway. Eur. J. Pharmacol., 2007, 567, 26-35.
95. Aubin, M-C.; Lajoie, C.; Clément, R.; Gosselin, H.; Calderone, A.; Perrault, L.P. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J. Pharmacol. Exp. Ther., 2008, 325, 961-968.
96. Das, S.; Das, D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets, 2007, 6, 168-173.
97. Das, S.; Falchi, M.; Bertelli, A.; Maulik, N.; Das, D.K. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung, 2006, 56, 700-706.
98. Venkatachalam, K.; Mummidi, S.; Cortez, D.M.; Prabhu, S.D.; Valente, A.J.; Chandrasekar, B. Resveratrol inhibits high glucose induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am. J. Physiol. Heart. Circ. Physiol., 2008, 294, H2078-H2087.
99. Gonzales, A.M.; Orlando, R.A. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. (Lond), 2008, 12, 5-17.
100. Chen, W-P.; Su, M-J.; Hung, L-M. In vivo electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur. J. Pharmacol., 2007, 554, 196-204.
101. Chen, Y.R.; Yi, F.F.; Li, X.Y.; Wang, C.Y.; Chen, L.; Yang, X.C.; Su, P.X.; Cai, J. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc. Drugs. Ther., 2008, 22, 479-485.
102. Potente, M.; Dimmeler, S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle, 2008, 7, 2117-2122.
103. Miyazaki, R.; Ichiki, T.; Hashimoto, T.; Inanaga, K.; Imayama, I.; Sadoshima, J.; Sunagawa, K. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc Biol., 2008, 28, 1263-1269.
104. Nicholson, S.K.; Tucker, G.A. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc. Nutr. Soc., 2008, 67, 42-47.
105. Ekshyyan, V.P.; Hebert, V.Y.; Khandewal, A.; Dugas, T.R. Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor dependent nitric oxide production. J. Cardiovasc. Pharmacol., 2007, 50, 83-93.
106. Moon, S-O.; Kim, W.; Sung, M.J.; Lee, S.; Kang, K.P.; Kim, D.H.; Lee, S.Y.; So, J-N.; Park, S.K. Resveratrol suppresses tumor necrosis factor-α-induced fractalkine expression in endothelial cells. Mol. Pharmacol., 2006, 70, 112-119.
107. Csiszar, A.; Smith, K.; Labinskyy, N.; Orosz, Z.; Rivera, A.; Ungvari, Z. Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-βB inhibition. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H1694-H1699.
108. Chow, S.E.; Hshu, Y.C.; Wang, J.S.; Chen, J.K. Resveratrol attenuates ox-LDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J. Appl. Physiol., 2007, 102, 1520-1527.
109. Ungvari, Z.; Orosz, Z.; Rivera, A.; Labinskyy, N.; Zhao, X.; Olson, S.; Podlutsky, A.; Csiszar, A. Resveratrol increases vascular oxidative stress resistance. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H2417-2424.
110. Xia, L.; Wang, X.X.; Hu, X.S.; Guo, X.G.; Shang, Y.P.; Chen, H.J.; Zeng, C.L.; Zhang, F.R.; Chen, J.Z. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br. J. Pharmacol., 2008, 155, 387-394.
111. Hsieh, Y-H.; Huang, S-S.; Wei, F-C.; Huang, L-M. Resveratrol attenuates ischemia-reperfusion-induced leukocyte-endothelial cell adhesive interactions and prolongs allograft survival across the MHC barrier. Circ. J., 2007, 71, 423-428.
112. Maulik, N. Reactive oxygen species drives myocardial angiogenesis? Antioxid. Redox. Signal., 2006, 8, 2161-2168.
113. Kaga, S.; Zhan, L.; Matsumoto, M.; Maulik, N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell Cardiol., 2005, 39, 813-822.
114. Penumathsa, S.V.; Koneru, S.; Samuel, S.M.; Maulik, G.; Bagchi, D.; Yet, S-F.; Menon, V.P.; Maulik, N. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: Role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free. Radic. Biol. Med., 2008, 45, 1027-1034.
115. Dong, W.; Gao, D.; Lin, H.; Zhang, X.; Li, N.; Li, F. New insights into mechanism for the effect of resveratrol preconditioning against cerebral ischemic stroke: Possible role of matrix metalloprotease-9. Med. Hypoth., 2008, 70, 52-55.
116. Cullen, J.P.; Morrow, D.; Jin, Y.; Curley, B.; Robinson, A.; Sitzmann, J.V.; Cahill, P.A.; Redmond, E.M. Resveratrol, a polyphenolic phytostilbene, inhibits endothelial monocyte chemotactic protein-1 synthesis and secretion. J. Vasc. Res., 2007, 44, 75-84.
117. Delmas, D.; Jannin, B.; Latruffe, N. Resveratrol: preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res., 2005, 49, 377-395.
118. Do, G-M.; Kwon, E-Y.; Kim, H-J.; Jeon, S-M.; Ha, T-Y.; Park, T.; Choi, M-S. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem. Biophys. Res. Commun., 2008, 374, 55-59.
119. Shen, M.Y.; Hsiao, G.; Liu, C.L.; Fong, T.H.; Lin, K.H.; Chou, D.S.; Sheu, J.R. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol., 2007, 139, 475-485.
120. Stef, G.; Csiszar, A.; Lerea, K.; Ungvari, Z.; Veress, G. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J. Cardiovasc. Pharmacol., 2006, 48, 1-5.
121. Novakovic, A.; Gojkovic Bukarica, L.; Kanjuh, V.; Heinle, H. Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol. Basic. Clin. Pharmacol. Toxicol., 2006, 99, 360-364.
122. Calderone, V.; Martelli, A.; Testai, L.; Martinotti, E.; Breschi, M.C. Functional contribution of the endothelial component to the vasorelaxing effect of resveratrol and NS 1619, activators of the large-conductance calcium-activated potassium channels. Naunyn. Schmiedebergs. Arch. Pharmacol., 2007, 375, 73-80.
123. Gojkovic-Bukarica, L.; Novakovic, A.; Kanjuh, V.; Mumbasirevic, M.; Lesic, A.; Neinle, H. A role of ion channels in the endothelium-independent relaxation of rat mesenteric artery induced by resveratrol. J. Pharmacol. Sci., 2008, 108, 124-130.
124. 2+ handling in A7r5 vascular myocytes. Eur. J. Pharmacol., 2007, 577, 91-97.
125. Buluc, M.; Demirel-Yilmaz, E. Resveratrol decreases calcium sensitivity of vascular smooth muscle and enhances cytosolic calcium increase in endothelium. Vasc. Pharmacol., 2006, 44, 231-237.
126. Klinge, C.M.; Blankenship, K.A.; Risinger, K.E.; Bhatnagar, S.; Noisin, E.L.; Sumanasekera, W.K.; Zhao, L.; Brey, D.M.; Keynton, R.S. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem., 2005, 280, 7460-7468.
127. Silan, C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol. Pharm. Bull., 2008, 31, 879-902.